| May 1 |
HOLX
|
Hologic Q2 2024 Earnings Preview |
| May 1 |
NBIX
|
Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle |
| May 1 |
NBIX
|
Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript |
| May 1 |
NBIX
|
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech |
| May 1 |
HOLX
|
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season? |
| May 1 |
NBIX
|
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say |
| May 1 |
NBIX
|
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates |
| May 1 |
NBIX
|
Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M |
| May 1 |
NBIX
|
Neurocrine Biosciences Reports First Quarter 2024 Financial Results |
| Apr 30 |
NBIX
|
UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval |
| Apr 30 |
NBIX
|
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules |
| Apr 30 |
NBIX
|
Neurocrine Biosciences Q1 2024 Earnings Preview |
| Apr 30 |
NBIX
|
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics |
| Apr 30 |
HOLX
|
Hologic to buy Endomagnetics for $310M |
| Apr 29 |
HOLX
|
Hologic to acquire breast surgical guidance firm Endomagnetics |
| Apr 29 |
HOLX
|
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company |
| Apr 29 |
HOLX
|
How You Should Play Hologic (HOLX) Ahead of Q2 Earnings |
| Apr 29 |
HOLX
|
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release |
| Apr 29 |
HOLX
|
Stay Ahead of the Game With Hologic (HOLX) Q2 Earnings: Wall Street's Insights on Key Metrics |
| Apr 29 |
HOLX
|
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp |
